Curcumin downregulates Smad pathways and reduces hepatic stellate cells activation in experimental fibrosis.


Journal

Annals of hepatology
ISSN: 1665-2681
Titre abrégé: Ann Hepatol
Pays: Mexico
ID NLM: 101155885

Informations de publication

Date de publication:
Historique:
received: 02 03 2020
revised: 06 05 2020
accepted: 28 05 2020
pubmed: 17 7 2020
medline: 24 8 2021
entrez: 17 7 2020
Statut: ppublish

Résumé

Curcumin, a polyphenol, is a natural compound that has been widely studied as a hepatoprotector; however, only a few studies have examined its ability to reduce fibrosis in previously established cirrhosis. The objective of this study was to investigate whether curcumin could reduce carbon tetrachloride (CCl CCl Curcumin reduced liver damage, oxidative stress, fibrosis, and restored normal activity of MMP-9 and MMP-2. Besides, curcumin restored NF-κB, IL-1, IL-10, TGF-β, CTGF, Col-I, MMP-13, and Smad7 protein levels. On the other hand, curcumin decreased JNK and Smad3 phosphorylation. Furthermore, curcumin treatment decreased α-SMA and Smad3 protein and mRNA levels. Curcumin normalized GSH, and NF-κB, JNK-Smad3, and TGF-β-Smad3 pathways, leading to a decrement in activated hepatic stellate cells, thereby producing its antifibrotic effects.

Identifiants

pubmed: 32673649
pii: S1665-2681(20)30065-X
doi: 10.1016/j.aohep.2020.05.006
pii:
doi:

Substances chimiques

Anti-Inflammatory Agents 0
Antioxidants 0
Cytokines 0
Protective Agents 0
Smad3 Protein 0
Smad3 protein, rat 0
Smad7 Protein 0
Smad7 protein, rat 0
Carbon Tetrachloride CL2T97X0V0
Curcumin IT942ZTH98

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

497-506

Informations de copyright

Copyright © 2020 Fundación Clínica Médica Sur, A.C. Published by Elsevier España, S.L.U. All rights reserved.

Auteurs

Erika Hernández-Aquino (E)

Laboratory of Experimental Hepatology, Department of Pharmacology, Cinvestav-IPN, Av. Instituto Politécnico Nacional, Mexico City, Mexico.

Marco A Quezada-Ramírez (MA)

Department of Physiology, Biophysics and Neurosciences, Cinvestav-IPN, Mexico City, Mexico.

Angélica Silva-Olivares (A)

Department of Infectomics and Molecular Pathogenesis, Cinvestav-IPN, Mexico City, Mexico.

Erika Ramos-Tovar (E)

School of Higher Education in Medicine-IPN, Mexico City, Mexico.

Rosa E Flores-Beltrán (RE)

Laboratory of Experimental Hepatology, Department of Pharmacology, Cinvestav-IPN, Av. Instituto Politécnico Nacional, Mexico City, Mexico.

José Segovia (J)

Department of Physiology, Biophysics and Neurosciences, Cinvestav-IPN, Mexico City, Mexico.

Mineko Shibayama (M)

Department of Infectomics and Molecular Pathogenesis, Cinvestav-IPN, Mexico City, Mexico.

Pablo Muriel (P)

Laboratory of Experimental Hepatology, Department of Pharmacology, Cinvestav-IPN, Av. Instituto Politécnico Nacional, Mexico City, Mexico. Electronic address: pmuriel@cinvestav.mx.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH